MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: [Therapeutic Response and Prognosis of Adult Acute Myeloid Leukemia with Chromosome Karyotype Abnormalities].
Author: Chen Y, Tao SD, Shi YY, Song LX, Deng Y, Ling LL, Ding BH, Chen KK, He ZM, Wang CL, Yu L.
Journal: Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1717-1721. PubMed ID: 31839028.
Abstract:
OBJECTIVE: To investigate the efficacy and prognosis of acute myeloid leukemia (AML) patients with chromosome karyotype abnormalities. METHODS: The clinical features and treatment responses of 91 patients with AML were collected and analyzed retrospectively. The efficacy and survival rate of the AML patients with normal and abnormal chromosome karyotype were compared. RESULTS: Chromosome translocations and monosomal karyotypes were the main heterogeneity of AML. There was no significant difference in complete remission rate and overall response rate between the normal and abnormal karyotype groups, but the recurrence rate was higher in abnormal karyotype group. There was no significant difference in response of AML patients received the standard "3+7 regimen" and pre-excitation chemotherapy in the treatment of normal and abnormal karyotype groups. The relapse free survival time (RFS) was longer in the normal karyotype group, but there was no significant difference in overall survival time (OS). CONCLUSION: The abnormal karyotype of AML is an independent prognostic factor, monosomal karyotype shows a poor prognosis, and the recurrence rate in AML patients with monosomal karyotype is higher. 题目: 伴有染色体核型异常的成人急性髓系白血病患者的疗效与预后. 目的: 探讨伴有染色体核型异常的急性髓系白血病患者的疗效及预后. 方法: 收集并回顾性分析91例AML患者的临床特征、治疗反应，比较正常核型与异常核型患者的疗效与生存率. 结果: 染色体易位及单体核型为AML的主要异常核型。正常核型组与异常核型组在完全缓解率、总体治疗反应率上均无明显差异，异常核型组复发率增高。标准"3+7方案"与预激方案诱导化疗在正常核型组与异常核型组治疗反应上无明显差异。无复发存活时间（RFS）在正常核型组较异常核型组延长，OS时间无明显差异. 结论: 染色体核型异常是AML的独立预后因素，单体核型预后较差、复发率较高.

[Abstract] [Full Text] [Related] [New Search]